Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens

Durrie Vision

Status and phase

Withdrawn

Phase 4

Conditions

Myopia

Treatments

Device: Nexisvision shield

Study type

Interventional

Funder types

Other

Identifiers

NCT01706237

NVS-SOVR-001

Details and patient eligibility

About

Evaluate visual outcomes and contrast sensitivity for subjects undergoing bilateral myopic LASIK with a Nexisvision Shield or bandage contact lens placed postoperatively. Early speed of visual recovery results indicate that the visual recovery in the first 4 hours after the LASIK procedure show the most variability. A patient's ability to drive after their LASIK procedure would potentially alleviate a challenge that patients often face in taking additional time off work or simply finding a ride to there LASIK procedure.

Full description

Laser in situ keratomileusis (LASIK) surgery has been performed worldwide since 1990. Historically, LASIK has been reported to decrease contrast sensitivity post operatively and patients have been advised to take the day off of work and potentially the day after LASIK. More recently, utilizing advanced laser technology for optimized corneal ablation and creation of the flap has the potential for improved LASIK surgery results and improved recovery time. Visual recovery and management of immediate post operative visual acuity is important for patient satisfaction.

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female in good general health, 18 years of age or older at the time of the pre-operative examination
Patient must be able to read, comprehend and willing to give HIPPA and informed consent
Patient is planning to undergo a bilateral LASIK procedure
Both eyes must have a manifest refractive error from -1.00 D to -7.00 spherical equivalent with less than or equal to 3.00D of refractive astigmatism as expressed in spectacle minus cylinder form
Both eyes must have a BSCVA of 20/20 or better
Both eyes must demonstrate refractive stability confirmed by clinical records, previous glasses, or investigator's discretion.
Patient must be willing to comply with study dosing and complete the entire course of the study.

Exclusion criteria

A patient with evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye
A patient seeking monovision
A patient with a known hypersensitivity to any of the components of the procedural or post-LASIK medications
A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye during the study period with the exception of ocular drops and/or medications provided by the investigator
A patient having any surgical procedure within a week preceding the scheduled LASIK surgery
A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom therapy for a systemic disease is not yet stabilized )
A patient with a history of prior intraocular or corneal surgery (including cataract extraction), active ophthalmic disease or abnormality (including, but not limited to, blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), clinically significant lens opacity, clinical evidence of trauma (including scarring), or evidence of glaucoma or propensity for narrow angle glaucoma in either eye
A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results
A patient with a history of any of the following medical conditions, or any other condition that could affect wound healing: uncontrolled diabetes, collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.